BioConnection
BioConnection is a Netherlands-based, EMA and US-FDA-approved CDMO providing aseptic fill & finish and lyophilization services for sterile injectable drug products, serving small-to-mid-sized biopharma companies across clinical and commercial scales from its Oss facility.
- Company typePrivate
- Founded2005
- HeadquartersOss, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What BioConnection does
BioConnection B.V. is a Netherlands-based Contract Development and Manufacturing Organization (CDMO) founded in 2005 and headquartered in Oss, with 101–250 employees. The company specializes in aseptic fill & finish services for sterile injectable drug products — including vials, syringes and cartridges — at both clinical and commercial scales, complemented by lyophilization (freeze-drying) capacity of up to 10 m² shelf area. The Oss production facility is dual-approved by the EMA and the US-FDA and operates four class A aseptic filling lines within a single site, enabling an unusually broad batch-size envelope from a single unit (hand fill, personalized medicine) up to 150,000 units per batch (automated commercial scale), with annual capacity certified in 2021 for up to 40 million liquid vials and 4 million freeze-dried vials.
BioConnection serves small-to-mid-sized biopharmaceutical and biotech companies that lack their own sterile manufacturing infrastructure, with named customers spanning respiratory therapeutics (Verona Pharma), oncology (BioLineRx, Lava Therapeutics, AIMM Therapeutics), vaccines (Nykode, AdaptVac), hematology (VarmX), and live biotherapeutic products (Infant Bacterial Therapeutics). The service offering extends beyond fill & finish to formulation and process development, analytical development and validation, container closure integrity and sterility testing, stability studies, secondary packaging with serialization, tech transfer, scale-up, and regulatory support, all coordinated by a dedicated Program Management team across the drug lifecycle.
Revenue is generated through project-based contract manufacturing fees priced per program, with costs varying by batch specifications, scale (clinical vs. commercial), fill volume, and service scope. Go-to-market is relationship-driven and direct: a Business Development team of four managers engages enterprise customers globally, supplemented by an active presence at major industry events (CPHI, BIO-Europe, BioProcess International, TIDES, World Orphan Drug Congress, among others). In April 2022 the company completed a capital raise led by Gimv with participation from Pharming Group, Mibiton and management, and in May 2024 entered a strategic partnership with AGC Biologics to offer integrated 'gene to vial' services; in March 2026 BioConnection ordered a new robotized isolator filling line and freeze-dryer expected operational in H2 2028.
BioConnection firmographics
Firmographics- Name
- BioConnection
- Legal name
- BioConnection B.V.
- Website
- https://bioconnection.eu
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BioConnection is a Netherlands-based, EMA and US-FDA-approved CDMO providing aseptic fill & finish and lyophilization services for sterile injectable drug products, serving small-to-mid-sized biopharma companies across clinical and commercial scales from its Oss facility.
- Ownership category
- akta.pro rank
BioConnection industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where BioConnection is headquartered
LocationHeadquarters
- HQ city
- Oss
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
BioConnection business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services (Fill & Finish): BioConnection generates revenue through contract manufacturing fees for aseptic fill & finish services, including automated filling, lyophilization, and small-scale hand fill. Services are priced per project/program, with costs varying based on batch size, product complexity, scale (clinical vs. commercial), and project scope. Revenue is project-based and non-recurring per contract, though ongoing programs with existing clients generate repeat business.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based contract manufacturing — pricing varies by program scope and specifications |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
BioConnection product offering
Product offeringCore offering
BioConnection is a specialized Contract Development and Manufacturing Organization (CDMO) providing aseptic fill & finish services for sterile drug products into vials, syringes, and cartridges at EMA and US-FDA-approved GMP facilities in Oss, the Netherlands. Core offerings include automated and manual aseptic filling (batch sizes from 1 unit up to 150,000 units per batch), lyophilization/freeze-drying (shelf areas 3-10 m²), and integrated additional services including formulation development, analytical testing, secondary packaging with serialization, technology transfer, scale-up, and regulatory support for clinical and commercial supply worldwide.
Product overview
BioConnection is a specialized CDMO (Contract Development and Manufacturing Organization) providing a comprehensive suite of sterile drug product manufacturing services. The core offering centers on Fill & Finish Services and Lyophilization Services for vials and syringes, supported by additional services including Development Services, Analytical Services, and Secondary Packaging. The company operates from an EMA and US-FDA-approved facility in Oss, Netherlands, and supports the entire drug lifecycle from toxicology studies through Phase I-III clinical manufacturing to commercial market production. The product portfolio is unified under a single service delivery model where all capabilities are coordinated through a dedicated program management team to ensure seamless project transitions.
Differentiator
Problem solved
Functional benefit
Products and services
- Fill & Finish Services Aseptic filling of sterile drug products into vials (2 RDIN to 50 RDIN) and prefilled syringes (0.5 ml to 10 ml) with batch sizes from 1 unit up to 150,000 units per batch, supporting both clinical and commercial scale manufacturing at EMA and US-FDA-approved GMP facilities for biopharmaceutical customers.
- Lyophilization (Freeze-Drying) Services Freeze-drying services with shelf areas ranging from 3 m² up to 10 m² across two filling lines, fully compliant with EMA and US-FDA regulations for lyophilized injectable products, supporting both clinical and commercial supply for biopharmaceutical clients.
- Development Services Formulation development for liquid and lyophilized injectables, process development for aseptic filling, and lyophilization cycle development to optimize product quality and stability for client drug products across clinical and commercial stages.
- Analytical Services Stability studies, container closure integrity testing (CCIT), method validation or transfer, sterility testing, bioburden determination, and bacterial endotoxin testing to support GMP manufacturing release and stability programs for client drug products.
- Secondary Packaging Labeling and packaging of vials and prefilled syringes for clinical and commercial use, with serialization services available to comply with country-specific regulatory requirements for global market supply.
- Hand Fill Services Specialized small-scale manual aseptic fill production for personalized medicines, ATMP support, and early-stage clinical trials in class B to D cleanrooms with class A manual fill, handling batch sizes from 1 unit up to around 1,000 units, including BSL-2 ready capability.
- Technology Transfer, Scale-up and PPQ Services Technology transfer, scale-up, and Process Performance Qualification (PPQ) execution to support seamless progression of client drug products from development through clinical stages to commercial manufacturing, including regulatory support for marketing authorization submissions.
Quantifiable outcome
- Up to 40 million vials per year for liquid products and up to 4 million vials per year for freeze-dried products from the large-scale filling line
- +1 more outcomes
Companies that use BioConnection
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles2 records
BioConnection technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BioConnection partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Infant Bacterial Therapeutics (IBT)coreIBT partnered with BioConnection for Process Performance Qualification (PPQ) of Drug Product for IBT's lead Live Biotherapeutic Product IBP-9414, intended for premature infants. PPQ manufacturing is conducted at BioConnection's Oss facility. This represents a key step in IBT's path to commercial supply, with IBT noting BioConnection currently supplies pharmaceutical products to European and US markets.
- AGC BiologicscoreStrategic partnership announced May 2024 between AGC Biologics (a leading global CDMO) and BioConnection. The partnership provides end-to-end biopharmaceutical development and manufacturing capabilities combining AGC Biologics' drug substance expertise with BioConnection's specialized aseptic fill & finish services. Customers receive a seamless 'gene to vial' value chain service with a single contract and project management team, accelerating timelines and reducing complexity.
Scale indicators6 records
Recent moves10 records
Expansion highlights5 records
BioConnection competitors and assessment
Company assessmentDirect peers
- Rommelag (Holopack): Rommelag is a leading aseptic fill-finish CDMO offering blow-fill-seal and vial filling services. Direct peer in sterile injectable manufacturing with comparable customer base.
- HALIX: HALIX is a Dutch CDMO specializing in GMP manufacturing of vaccines and biopharmaceuticals, including aseptic fill-finish. Direct geographic and capability peer based in the Netherlands.
- Recipharm: Recipharm is a European CDMO offering aseptic fill-finish and lyophilization services to biopharma customers. Directly comparable to BioConnection in fill-finish capabilities, geographic focus, and customer segments.
- Vibalogics: Vibalogics is a specialized CDMO focused on viral vaccines and gene therapies with aseptic fill-finish capabilities. Direct peer in serving biotechs with complex sterile injectable modalities.
- AGC Biologics: AGC Biologics is a global CDMO with microbial and mammalian biologics manufacturing that recently partnered with BioConnection to provide integrated 'gene to vial' services. They are direct peers in CDMO services with a complementary (rather than overlapping) scope.
- SK biotek: SK biotek is an Asia-based CDMO with strong fill-finish capabilities serving global pharma and biotech. Comparable in scale and service mix, with a similar focus on small-to-mid biopharma customers.
Regional players
- Millmount Healthcare (Uniphar): Millmount Healthcare, part of Uniphar, is an Irish CDMO providing sterile injectable fill-finish and lyophilization. Comparable capability profile, focused primarily on European market similar to BioConnection.
Broad incumbents
- Lonza: Lonza is a global CDMO leader offering biologics manufacturing and fill-finish services. Overlaps with BioConnection in sterile injectable fill-finish, but operates as a broad incumbent across modalities and scales.
- Catalent: Catalent is one of the largest global CDMOs with extensive aseptic fill-finish capacity across multiple modalities. Serves similar biotech customers but at materially greater scale and broader geographic footprint.
- Eurofins CDMO: Eurofins CDMO (formerly Alpharma) provides contract development and manufacturing services including sterile fill-finish. Broad incumbent with overlapping capabilities and similar European presence.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks4 records
Key highlights6 records
Customer concentration
BioConnection social profiles
Digital presenceBioConnection compliance and trust
Trust signalCompliance6 records
BioConnection financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioConnection leadership team
Management profileNumber of profiles
Profiles10 records
BioConnection funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioConnection M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioConnection
What does BioConnection do?
BioConnection is a specialized Contract Development and Manufacturing Organization (CDMO) providing aseptic fill & finish services for sterile drug products into vials, syringes, and cartridges at EMA and US-FDA-approved GMP facilities in Oss, the Netherlands. Core offerings include automated and manual aseptic filling (batch sizes from 1 unit up to 150,000 units per batch), lyophilization/freeze-drying (shelf areas 3-10 m²), and integrated additional services including formulation development, analytical testing, secondary packaging with serialization, technology transfer, scale-up, and regulatory support for clinical and commercial supply worldwide.
Is BioConnection a public or private company?
BioConnection is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioConnection founded?
BioConnection was founded in 2005. It employs 101 to 250 people.
Where is BioConnection based?
BioConnection is headquartered in Oss, Netherlands, in the Europe region.
How does BioConnection make money?
One revenue line is on record: contract Manufacturing Services (Fill & Finish).
Who are BioConnection's main competitors?
Direct peers on record are Rommelag (Holopack), HALIX, Recipharm, Vibalogics, AGC Biologics and SK biotek. Millmount Healthcare (Uniphar) is listed as a regional player. Broad incumbents are Lonza, Catalent and Eurofins CDMO.
Does BioConnection have an API?
No public API is recorded for BioConnection.
What industry is BioConnection in?
BioConnection's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.